Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11431)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 21, 2024 (publication date) through Mar 11, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313 [PMID: 39086752 DOI: 10.3748/wjg.v30.i27.3304] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313 [PMID: 39086752 DOI: 10.3748/wjg.v30.i27.3304] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm |
| Number | Citing Articles |
| 1 |
Karolina Kornatowska, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Natalia Pawelec, Weronika Mazur, Mateusz Tyniec, Kamal Morshed. A Novel Approach to H. pylori Eradication: A Narrative Review of Vonoprazan-Based Therapies. Gastroenterology Insights 2025; 16(3): 35 doi: 10.3390/gastroent16030035
|
| 2 |
Jin-Yan Zhang, Jin-Hai Chen, Yu-Lin Huang, Ji Li, Dong Xu, Zhong Xu, Xiao-Yi Lei.
Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for
Helicobacter pylori
treatment: a randomized clinical trial
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251354868
|
| 3 |
Zhaoli Ma, Shiling Wang, Furui Wang, Qian Ren.
Research progress of potassium-competitive acid blockers in the treatment of
Helicobacter pylori
. Annals of Medicine 2025; 57(1) doi: 10.1080/07853890.2025.2544886
|
| 4 |
Azzam Zrineh, Rami Akwan, Muhammad M. Elsharkawy, Mostafa Adel T. Mahmoud, Hadeel Ayesh, Mazen Momtaz Shehata, Hamza Karmi, Elsayed S. Moubarak. Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan–amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis. BMC Infectious Diseases 2026; doi: 10.1186/s12879-026-13085-0
|
| 5 |
Zhiqiang Song, Xiuli Zuo, Zhenyu Zhang, Xuehong Wang, Ya Lin, Yueyue Li, Xiaojun Xu, Yun Huang, Qiuyan Wang, Yanyan Shi, Liya Zhou. Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter 2025; 30(5) doi: 10.1111/hel.70070
|
| 6 |
Chih-An Shih, Deng-Chyang Wu, Chang-Bih Shie, Ping-I Hsu. Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review. Microorganisms 2025; 13(4): 715 doi: 10.3390/microorganisms13040715
|
| 7 |
Zafeer-ul-Hassan Iqbal, Syed Muhammad Hassan Bukhari, Shama Shahid Rana, Rana Asjad Dilshad, Amna Saeed, Mars Christian Aragon Sta Ines, Ali Haroon. Comparison of Vonoprazan Triple Therapy, Bismuth Quadruple Therapy, and Amoxicillin Therapy for Helicobacter pylori Infection: A Systematic Review. Cureus 2025; doi: 10.7759/cureus.83142
|
| 8 |
Chih-An Shih, I-Ting Wu, Deng-Chyang Wu, Wei-Yi Lei, Feng-Woei Tsay, Tzung-Jiun Tsai, Chung-Hung Tsai, Ya-Chi Wu, Wei-Chen Tai, Ping-I Hsu. Evolution of Amoxicillin-Based Mono-Antibiotic Regimens for Helicobacter pylori Eradication: From Ineffectiveness to Innovation—A Systematic Review. Microorganisms 2026; 14(3): 625 doi: 10.3390/microorganisms14030625
|
| 9 |
Ming-ming Zhang, Mei-ding Wang, Shi-yu Yang, Jia-qiang Hu, Bao-qiang Zhu, Yuan-kui Wei, Chang-lan Zhang, En-wu Long. The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. Journal of Infection and Public Health 2025; 18(7): 102768 doi: 10.1016/j.jiph.2025.102768
|
| 10 |
Xueyan Lin, Huping Huang, Yijuan Liu, Yanling Zeng, Shiyun Lu, Xuefeng Xu, Yun Lin, Feng Qiu, Fangfang Cai, Jie Pan, Shaozhong Huang, Shaowei Lin, Aiping Lin, Zhihui Lin, Xueping Huang. Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China. Helicobacter 2024; 29(6) doi: 10.1111/hel.13151
|